$NVDA NEWS Nvidia stock hits another record as Wall Street stays bullish NasdaqGS - Nasdaq Real Time Price ? USD Century Therapeutics, Inc. (IPSC) Follow Compare 1.5400 -0.0600 (-3.75%) At close: 4:00 PM EDT 1.5400 0.00 (0.00%) After hours: 4:02 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer - Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer - - Chad Cowan, Ph.D., cell therapy pioneer, founder, and former CEO of Clade Therapeutics, appointed as Chief Scientific Officer - - Hy Levitsky, M.D., President of Research and Development, to transition to an advisor to Century - PHILADELPHIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative GlobeNewswire ? 25 days ago IPSC -3.75% Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates Century Therapeutics (IPSC) delivered earnings and revenue surprises of 24% and 40.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago IPSC -3.75% Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates – Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients – – Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101 demonstrating encouraging preliminary efficacy and tolerability data in heavily pretreated relapsed/refractory – – Completed dose escalation for ELiPSE-1 and advancing into dose expansion in 2H 2024 – – Ended second qu GlobeNewswire ? 2 months ago IPSC -3.75% After losing 17% in the past year, Century Therapeutics, Inc. (NASDAQ:IPSC) institutional owners must be relieved by the recent gain Key Insights Institutions' substantial holdings in Century Therapeutics implies that they have significant influence... Simply Wall St. ? 3 months ago IPSC -3.75% Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Zacks ? 3 months ago IPSC -3.75% Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA method for detecting total body PK suggests CNTY-101 persists outside the bloodstream Enrollment continues in dose escalation phase of ELiPSE-1 at dose levels 3B (three weekly infusions of 1 billion cells) and 4A (single i GlobeNewswire ? 4 months ago IPSC -3.75% Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ... Comprehensive Analysis of Financial Performance and Strategic Milestones GuruFocus.com ? 5 months ago IPSC -3.75% Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE)Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD300a as a universal strategy for preventing NK mediated rejection in allogeneic cell therapies PHILADELPHIA, May 10, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developi GlobeNewswire ? 5 months ago IPSC -3.75% Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates Century Therapeutics (IPSC) delivered earnings and revenue surprises of 10% and 185%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 5 months ago IPSC -3.75% Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion? platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase GlobeNewswire ? 5 months ago IPSC -3.75% Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows: Fireside Chat o GlobeNewswire ? 5 months ago IPSC -3.75% Century buys a startup, raises funding in cell therapy expansion The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital. BioPharma Dive ? 6 months ago IPSC -3.75% Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026 Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and n GlobeNewswire ? 6 months ago IPSC -3.75% Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024. The posters highlight the Company’s end-to-end capabilities in iPSC reprogramming and differentiation, gene GlobeNewswire ? 6 months ago IPSC -3.75% Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and... Simply Wall St. ? 6 months ago IPSC -3.75% Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. “We are fortunate to have Tim and Paul join us at this key st GlobeNewswire ? 6 months ago RPHM IPSC -3.75% SGMT Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar? Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. Zacks ? 6 months ago IPSC -3.75% Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET. A replay of the event will be available on the “Eve GlobeNewswire ? 6 months ago IPSC -3.75% Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion? may support a multi-dosing regimen without the need for continued lymphodepletion - - Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE); On track to initiate Phase 1 CALiPSO-1 clinical trial in the first half of 2024 - - GlobeNewswire ? 7 months ago IPSC -3.75% Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares Century Therapeutics Inc (NASDAQ:IPSC), a biotechnology company focused on developing allogeneic cell therapies for cancer and other diseases, has reported an insider sale according to a recent SEC filing. GuruFocus.com ? 7 months ago IPSC -3.75% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return IPSC S&P 500 YTD -53.61% +22.73% 1-Year +4.05% +38.58% 3-Year -92.31% +29.05%
